Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors
Black Diamond Therapeutics (BDTX) announced the appointment of Wendy L. Dixon, Ph.D., to its Board of Directors following the resignation of Brad Bolzon, Ph.D. This change aims to bolster the company's leadership as it advances its MasterKey therapies. Dr. Dixon, with over 40 years of experience in the biopharmaceutical industry and a strong background in marketing and drug development, is expected to enhance strategic initiatives, particularly in the ongoing clinical development of BDTX-1535 for glioblastoma multiforme. Dr. Epstein praised Bolzon's contributions during his tenure.
- Wendy L. Dixon brings over 40 years of biopharmaceutical experience, strengthening board expertise.
- Her background in regulatory affairs and drug development is expected to advance BDTX's pipeline.
- Appointment aligns with the company's goal to innovate in precision oncology treatment.
- Brad Bolzon's resignation may raise concerns about continuity in board governance.
- The transition could create uncertainty as the new board member integrates into company strategies.
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Wendy L. Dixon, Ph.D., to its Board of directors. Additionally, Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures and a member of Black Diamond’s Board of Directors since 2017, has resigned from the Board.
“Brad’s contributions to Black Diamond over the last five years have been invaluable. He has supported the company from its founding through many stages of our development including our path to becoming a public company,” said David M. Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. “On behalf of the Board, I would like to thank Brad for his collaboration, expertise and counsel as the company has grown.”
“I am thrilled to welcome Wendy to the Black Diamond Board of Directors. As the former Chief Marketing Officer of Bristol Myers Squibb and a seasoned director of public biopharmaceutical companies, Wendy’s proven ability to navigate regulatory and development pathways and guide biopharmaceutical companies through various stages of growth and development will be a strong addition to our board of directors as we further advance our exciting pipeline of novel MasterKey therapies,” added Dr. Epstein.
Dr. Dixon has over 40 years of biopharmaceutical industry experience. Over the last four decades, she has combined her technical background and experience in drug development with leadership roles in regulatory affairs and commercial capabilities. Dr. Dixon currently serves on the Board of Directors of Alkermes plc, Incyte Corp., and Arvinas Inc. She is also the Principal of Great Meadow Consulting where she assists small- and large-cap companies with strategic planning, organizational design and talent mentoring. She previously served as the Chief Marketing Officer and President of Global Marketing at Bristol Myers Squibb for eight years and as a Senior Vice President of Marketing at Merck for five years. Prior to that, she held various executive management positions at West Pharmaceuticals, Osteotech and Centocor, as well as various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon holds a Ph.D. in Biochemistry and an M.Sc. and B.Sc. in Natural Science from the University of Cambridge.
“Black Diamond offers a unique approach to precision oncology and I am delighted to be joining the Board of Directors at this exciting time in the company’s evolution,” said Dr. Dixon. “Black Diamond’s MasterKey therapies offer the potential to meaningfully disrupt the oncology treatment landscape, and coupled with its strong leadership team, I believe that Black Diamond is well-positioned for success. I was particularly drawn to the company’s efforts to address the huge unmet medical need for new treatments for patients suffering from glioblastoma multiforme (GBM) with the recently initiated clinical development of its product candidate BDTX-1535. The company has laid out clear priorities and direction for pipeline expansion and the advancement of its MasterKey therapies, and I look forward to collaborating and advising on some of these key initiatives.”
About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Julie Seidel
investors@bdtx.com
For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com
FAQ
What leadership changes occurred at Black Diamond Therapeutics on April 7, 2022?
Who is Wendy L. Dixon and what expertise does she bring to BDTX?
What does the appointment of Wendy L. Dixon mean for Black Diamond's future?
What is BDTX-1535 and why is it significant for Black Diamond Therapeutics?
